Mo et al. demonstrated that KCa3.1 knockdown, achieved through shRNA‐mediated silencing or pharmacological inhibition with TRAM‐34, significantly reduced intracellular Ca2+ levels in pancreatic cancer cells (Mo et al. 2022). This evidence concerns the gene KCNN4 and pancreatic neoplasm.